Tempus AI, an artificial intelligence and precision medicine firm, has unveiled a new initiative to leverage algorithms to bridge care gaps in immunohistochemistry (IHC) testing.
The programme will use tools to identify patients more likely to test positive for actionable biomarkers and who should receive confirmatory testing based on clinical guidelines.
Part of the broader Tempus Next platform, the initiative will provide clinicians with actionable insights at the point of care.
The new Next programme, now available, initially focuses on identifying care gaps related to human epidermal growth factor receptor 2 (HER2) testing, as recommended for patients with specific metastatic cancers.
In the initial rollout, Tempus developed an algorithm integrated into xR, the company’s RNA sequencing assay.
The RNA-based algorithm will help identify patients who are particularly likely to benefit from on-guideline IHC testing.
The algorithm, part of Tempus’ xR CAP/CLIA Laboratory Developed Test, utilises RNA data to predict IHC/ISH positivity in tumour samples.
Furthermore, the programme is being launched at select pilot sites, where physicians will be informed about patients flagged by the algorithm as more likely to be HER2 positive.
It will allow clinicians to consider ordering confirmatory IHC testing from their preferred laboratory.
The development of this initiative was supported by Tempus and one or more life sciences company sponsors.
Tempus AI chief medical officer Ezra Cohen said: “This programme is truly the intersection of all three of our business units – genomics, AI applications, and data – leveraging our deep connectivity with providers, comprehensive testing portfolio, and AI-enabled data analytics to deliver a tool that physicians can use in real-time to provide patients with the most up-to-date, guideline-directed care.
“This programme is truly the intersection of all three of our business units – genomics, AI applications, and data – leveraging our deep connectivity with providers, comprehensive testing portfolio, and AI-enabled data analytics to deliver a tool that physicians can use in real-time to provide patients with the most up-to-date, guideline-directed care.”
Recently, the precision medicine firm signed an expanded data and sequencing collaboration with Remix Therapeutics.
In June this year, Tempus AI expanded its collaboration with AstraZeneca for biomarker testing for non-small cell lung cancer (NSCLC).
